Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.

After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.